Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064560 | 0.85 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6287334 | 0.82 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6687929 | 0.82 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1027277 | 0.81 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9375398 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27870758 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27917300 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL12207830 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5638275 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5638270 | 0.78 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1321454-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | Kaneka Corporation (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-6515179-B2 | Reacting nitrobenzenesulfonyl group containing compound contacting with alkali metal alkoxide | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20030009056-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | KANEKA CORPORATION (JP) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009056-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | NAAA, TST, AADAC | CA1 1849/4885CA2 644/4885MMP1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.